PART I . Overview Indivior Pharmaceuticals, Inc. and its subsidiaries (together, "Indivior" or the "Company") is the market leader in long-acting injectable medications for opioid use disorder (OUD). Indivior is focused on delivering evidence-based pharmacotherapies for OUD and is committed to advancing the neurobiological understanding of OUD as a chronic, relapsing, but treatable brain disease. For more than 25 years, Indivior has led innovation in addiction medicine, developing differentiated...
Q2 FY2026 — expected 2026-09-27
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001628280-26-012237 | EDGAR | 82K words |
| 2025-03-03 | 2024-12-31 | 0001625297-25-000016 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-10-30 | 2025-09-30 | 0001628280-25-047530 | EDGAR | 16K words |
| 2025-07-31 | 2025-06-30 | 0001625297-25-000050 | EDGAR | — |
| 2025-05-01 | 2025-03-31 | 0001625297-25-000030 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-17 | 0001625297-26-000015 | EDGAR | 45K words |
| 2026-03-13 | 0001625297-26-000012 | EDGAR | — |
| 2026-03-12 | 0001625297-26-000008 | EDGAR | — |
| 2026-02-26 | 0001193125-26-073363 | EDGAR | — |
| 2026-01-26 | 0001193125-26-021660 | EDGAR | — |
| 2026-01-08 | 0001193125-26-006993 | EDGAR | — |
| 2025-12-22 | 0001625297-25-000078 | EDGAR | — |
| 2025-12-18 | 0001625297-25-000076 | EDGAR | — |
| 2025-12-15 | 0001625297-25-000072 | EDGAR | — |
| 2025-11-20 | 0001625297-25-000069 | EDGAR | — |
371 total filings indexed. 356 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001625297 |
| Ticker | INDV |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.indivior.com |
| Listed | 2014-12-24 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report